All In Biotech

Drug Trial Radar · NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

474

Planned (sponsor's estimate)

Start

Apr 3, 2024

Primary completion

Jun 2028

Study completion Jun 2029

Sponsor

Lead sponsor
A2 Biotherapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Tempus AI
First posted
Sep 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose

Conditions

  • Solid Tumor, Adult
  • Colorectal Cancer
  • NSCLC
  • Non Small Cell Lung Cancer
  • NSCLC, Recurrent
  • Non-Small Cell Squamous Lung Cancer
  • Pancreas Cancer
  • Pancreatic Neoplasm
  • Colorectal Adenocarcinoma
  • CRC
  • Colon Cancer
  • Rectal Cancer
  • Cancer
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Mesothelioma
  • Mesothelioma, Malignant
  • Ovary Cancer
  • Lung Cancer
  • MESOM

Interventions

  • A2B694Biological

    Autologous logic-gated Tmod CAR T cells

  • A2B543Biological

    Autologous logic-gated Tmod CAR T cells

  • xT CDx with HLA-LOH AssayDiagnostic test

    An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose levelTime frame: From the time of Informed consent until 24 months (2 years) post infusion
  2. Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: 21 days post infusion
  3. Phase 2: The Overall Response Rate (ORR) for patientsTime frame: 24 months post infusion

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Health

    Gilbert, Arizona

  • UCSD Moores Cancer Center

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • Stanford University

    Stanford, California

  • Mayo Clinic

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • NYU Langone Medical Center

    New York, New York

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Fred Hutchinson Cancer Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.